The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | FRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AML
Sangeetha Venugopal, MD, MS, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses preliminary results from the Phase I FRIDA study (NCT05546580) evaluating iadademstat in combination with gilteritinib in patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). She highlights encouraging safety and response rates, suggesting this combination may offer an improved treatment option beyond gilteritinib alone. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The FRIDA study is an interesting study because this is the first results of the iodine stat which is an LST1 inhibitor in combination with gilteritinib in patients with relapsed refractory FLT3 mutated AML. So in this population gilteritinib is already the standard of care, which works, but then we still need better standards, better options for patients to move beyond the standard of care, which is the premise for this study...
The FRIDA study is an interesting study because this is the first results of the iodine stat which is an LST1 inhibitor in combination with gilteritinib in patients with relapsed refractory FLT3 mutated AML. So in this population gilteritinib is already the standard of care, which works, but then we still need better standards, better options for patients to move beyond the standard of care, which is the premise for this study. The preliminary results are very encouraging in terms of response rate, and because the response rate is one of the composite complete remission rate is one of the reasons that gilteritinib was approved so compared to gilteritinib this especially in the relapse refractory population irinotecan does not stack with gilteritinib combination, the combination has better response rate I do think it would be a great option for patients who cannot tolerate gilteritinib or gilteritinib fails them.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
